Integrated Pan-Cancer Analysis and Experimental Verification of the Roles of Retinoid-Binding Proteins in Breast Cancer

Our plain-English summary of Integrated Pan-Cancer Analysis and Experimental Verification of the Roles of Retinoid-Binding Proteins in Breast Cancer, by Y. Xiang, D. Du, Y. Su, et al (Cancers, 2025).

The study

• Authors: Y. Xiang, D. Du, Y. Su, L. Guo, S. Chen
• Journal: Cancers
• Published: 2025;17(22)
• Cited by: 1 article, as counted by NIH iCite
• Read it: PubMed · Publisher · Free full text

Abstract

Background: Retinoid-binding proteins (RBPs) regulate retinoid metabolism and signaling, but their roles across human cancers remain incompletely defined.

Methods: We conducted a comprehensive analysis using bioinformatics tools and experimental validations, examining RBP expression profiles across cancer types based on data from The Cancer Genome Atlas (TCGA). We employed survival analysis using the Kaplan-Meier method and utilized single-cell RNA sequencing (scRNA-seq) to investigate the roles of RBP4 and RBP7 in the tumor microenvironment.

Results: Our analysis revealed significant downregulation of RBPs in multiple cancers, with RBP4 and RBP7 showing notable expression variations linked to tumor stages and grades. Cox analysis identified RBP4 as a protective gene in kidney renal papillary cell carcinoma (KIRP), liver hepatocellular carcinoma (LIHC), and mesothelioma (MESO), while RBP7 exhibited protective effects in breast cancer (BRCA) and uveal melanoma (UVM).

Conclusions: This pan-cancer and single-cell integrative analysis highlights the complex roles of RBPs in cancer progression and their potential as prognostic biomarkers, particularly RBP4 and RBP7 in breast cancer. These findings warrant further investigation into the functional mechanisms of RBPs, which may provide valuable strategies for therapeutic interventions.

In plain English

This study did not examine asbestos. It was a computer-based (bioinformatics) analysis of public cancer databases, mainly The Cancer Genome Atlas (TCGA), plus a laboratory check in breast cancer tissue. The authors studied nine genes for retinoid-binding proteins, which handle vitamin A-related compounds, across many cancer types. RBP7 expression was lower in tumor tissue in 14 tumor types, including breast cancer. In a univariate Cox survival analysis, higher RBP4 expression was linked to lower risk in kidney renal papillary cell carcinoma, liver hepatocellular carcinoma and mesothelioma; the text gives no numbers for these results. In the same analysis, higher RBP7 expression was linked to lower risk in breast cancer, kidney renal clear cell carcinoma and uveal melanoma. In tissue from 47 breast cancer patients, higher RBP7 went with better prognosis. In an online breast cancer database, RBP7 had a hazard ratio of 0.86 (p less than 0.05). The authors concluded these proteins hold promise as prognostic markers in certain cancers. They noted the work rested mainly on computer analysis, lacked experiments on how the genes act, and allowed no inference about cause.

We wrote this plain-English summary from the full article with the help of AI, and a second AI model checked each sentence against the article. It is not the authors' wording; the abstract and the article are their own account.

What the study did and found

• Design: Bioinformatics analysis of public gene-expression and survival databases (pan-cancer TCGA, single-cell RNA sequencing, cBioPortal) with tissue microarray immunohistochemistry validation in breast cancer specimens
• Who was studied: TCGA pan-cancer samples across many tumor types (including mesothelioma); single-cell data from 5 normal breast and 4 triple-negative breast cancer samples (GSE161529); tissue specimens from 47 breast cancer patients enrolled between 2005 and 2012 (ethics approval from West China Hospital, Sichuan University)
• Exposure: No asbestos or other fiber exposure was studied. The variable examined was the expression level of nine retinoid-binding protein genes (RBP1, RBP2, RBP3, RBP4, RBP5, RBP7, RLBP1, CRABP1, CRABP2).
• Main results:
  • In univariate Cox analysis across TCGA cancers, the authors described RBP4 as a protective gene (expression associated with lower prognostic risk) in kidney renal papillary cell carcinoma (KIRP), liver hepatocellular carcinoma (LIHC) and mesothelioma (MESO). Hazard ratios are shown only in a figure and are not given in the text.
  • In the same univariate Cox analysis, RBP7 expression was associated with lower prognostic risk (described by the authors as a protective role) in breast cancer (BRCA), kidney renal clear cell carcinoma (KIRC) and uveal melanoma, and was a high-risk factor in colon (COAD) and stomach (STAD) adenocarcinoma.
  • RBP7 expression was reduced in tumor compared with normal tissue in 14 tumor types, including breast cancer.
  • In Kaplan–Meier analysis of TCGA breast cancer, RBP1, RBP4 and RBP7 showed protective effects.
  • In the tissue microarray of 47 breast cancer patients, higher RBP7 expression correlated with better prognosis.
  • In the online Kaplan–Meier Plotter breast cancer database, RBP7 was a protective factor for breast cancer survival (HR = 0.86, p less than 0.05).
  • In single-cell data from triple-negative breast cancer, RBP4 was mainly expressed in endothelial cells.
• The authors' conclusion: The authors concluded that RBPs hold promise as prognostic biomarkers in certain malignancies, with RBP4 and RBP7 of particular clinical relevance in breast cancer.
• Limitations the authors state:
  • TCGA data come from specific ethnic and geographic backgrounds, and clinical characteristics are not uniformly distributed or completely annotated, which could cause bias.
  • Findings come mainly from computational analysis. Mechanistic functional experiments were not done.
  • The analysis was retrospective and correlational, so no temporal or interventional inference can be made.

Topics

Medical terms in this study, explained in our Lexicon: Tumor Microenvironment, Carcinoma, Mesothelioma, Biomarker.

Related studies

• Evaluation of androgen receptor and GATA binding protein 3 as immunohistochemical markers in the diagnosis of metastatic breast carcinoma to the lung — Y. Hattori, A. Yoshida, et al. (2015)
• Retinoid signaling and activator protein-1 expression in ferrets given beta-carotene supplements and exposed to tobacco smoke — X.D. Wang, C. Liu, et al. (1999)
• Integrated pancancer analysis reveals the oncogene characteristics and prognostic value of DIP2B in breast cancer — C. Song, F. Shang, et al. (2023)
• Methylthioadenosine Phosphorylase and Breast Cancer 1 Protein-Associated Protein 1 as Biomarkers for the Peritoneal Mesothelioma — Y. Chen, X. Du, et al. (2023)
• Corrigendum: Why Be One Protein When You Can Affect Many? The Multiple Roles of YB-1 in Lung Cancer and Mesothelioma — T.G. Johnson, K. Schelch, et al. (2019)
• Leucine-rich glioma-inactivated protein 1 antibody-positive limbic encephalitis in a patient with an early-stage asymptomatic breast cancer — M.F. Niño Uribe, G. Van Cutsem, et al. (2025)

Browse more research in Cancers, or return to medical research.